Eduovisual
Human Development
Preconception care and counseling
— Organogenesis occurs at weeks 3–8 post-conception, often before the first prenatal visit (~8–10 weeks). Many teratogenic and metabolic exposures have already occurred.
— Nearly 45% of US pregnancies are unintended, so preconception counseling must be opportunistic at every primary care visit for reproductive-age women, not reserved for those "planning."
— Any well-woman, contraceptive, or chronic-disease visit in a woman aged ~15–50 who has reproductive capacity
— After a pregnancy loss, preterm birth, stillbirth, or adverse outcome (interconception care)
— Before discontinuing contraception or after a positive pregnancy intention screen ("Do you want to become pregnant in the next year?" — the One Key Question screen)
— Reproductive life plan and contraception
— Folic acid & nutrition
— Immunizations
— Chronic disease optimization (DM, HTN, thyroid, epilepsy, depression, SLE, asthma)
— Medication review for teratogens
— Genetic/family history & carrier screening
— Infectious disease screening (HIV, STIs, hepatitis, TB)
— Substance use, IPV, mental health, social determinants
— Environmental and occupational exposures
Step 3 management: On any ambulatory visit with a reproductive-age woman not using reliable contraception, document a reproductive life plan, start folic acid 400 mcg daily, update vaccines, and reconcile medications for teratogenicity — even if pregnancy is "not currently planned."
— Healthy 28-year-old at annual exam who mentions "thinking about kids next year"
— Woman with chronic disease (DM, HTN, epilepsy, SLE, hypothyroidism, depression) asking about pregnancy safety
— Patient on a known teratogen (isotretinoin, warfarin, ACEi/ARB, valproate, methotrexate, topiramate, mycophenolate, lithium)
— Prior adverse pregnancy outcome: preterm birth, preeclampsia, GDM, stillbirth, NTD, recurrent loss
— High-risk ethnic/family history for genetic disease (Ashkenazi Jewish, French Canadian, African, Mediterranean, SE Asian)
— Advanced reproductive age (≥35) or very young
— Postpartum visit (transitioning to interconception care)
— Pregnancy plan: desire, timing, partner, prior outcomes (GTPAL)
— Past medical: chronic disease control, surgeries (bariatric, cervical, uterine)
— Past obstetric: preterm birth, preeclampsia, GDM, cesarean, hemorrhage, depression
— Prescription/OTC/supplements: teratogens, dosing of folate
— Personal habits: tobacco, alcohol, cannabis, opioids, caffeine, exercise, diet, BMI
— Plus: Family history (NTDs, intellectual disability, congenital heart, hemoglobinopathies, BRCA, CF, fragile X, hereditary cancer), social (IPV, food/housing insecurity, immigration, occupation), environmental (lead, mercury fish, solvents, radiation), sexual/STI history
Board pearl: A prior pregnancy with a neural tube defect raises the recurrence risk roughly 10-fold; this woman needs high-dose folic acid 4 mg (4000 mcg) daily starting ≥1 month before conception, not the standard 400 mcg.
— BP: identify chronic HTN; goal <140/90 (often <130/80) before conception; document baseline pre-pregnancy BP
— Heart rate, BMI: calculate at every visit
— Pulse oximetry if pulmonary/cardiac disease
— BMI <18.5: nutritional counseling, evaluate eating disorder, low birth weight risk
— BMI 25–29.9: lifestyle counseling
— BMI ≥30: increased risk of infertility, GDM, preeclampsia, NTDs, stillbirth, cesarean; counsel 5–10% weight loss before conception; higher folate (often 1 mg) considered
— Post-bariatric surgery: wait 12–24 months before conception; screen for B12, folate, iron, vitamin D, thiamine deficiencies
Step 3 management: For a woman with chronic HTN planning pregnancy, switch from ACEi/ARB/direct renin inhibitor to labetalol, nifedipine, or methyldopa before conception, not after a positive pregnancy test — second/third trimester ACEi exposure causes oligohydramnios, renal dysgenesis, and skull hypoplasia.
— CBC — anemia, thrombocytopenia, MCV (microcytosis → hemoglobinopathy workup)
— Blood type and Rh, antibody screen — anticipate Rh isoimmunization
— Rubella IgG, varicella IgG — if non-immune, vaccinate and avoid pregnancy 4 weeks
— Hepatitis B surface antigen, hepatitis C antibody (USPSTF: HCV all adults ≥18 once)
— HIV (universal screen 15–65)
— Syphilis, gonorrhea, chlamydia if risk factors or ≤25
— TSH if symptoms, autoimmune disease, infertility, or prior thyroid disease (not universal in asymptomatic women per ATA/ACOG)
— Urinalysis — proteinuria baseline if HTN or DM; asymptomatic bacteriuria treated only in pregnancy, not preconception
— Hemoglobin A1c in women with DM (target <6.5% preconception to minimize congenital anomalies)
— Lead level if risk (immigrant, renovation, pica, occupational)
— Cystic fibrosis, spinal muscular atrophy (SMA), hemoglobinopathies — ACOG recommends offering to all
— Expanded panethnic panels increasingly standard
— Fragile X if family history of intellectual disability/premature ovarian insufficiency
— Tay-Sachs, Canavan, Gaucher in Ashkenazi Jewish
Board pearl: Live vaccines (MMR, varicella, LAIV) are contraindicated in pregnancy; give preconception and counsel to avoid pregnancy for 4 weeks afterward. Inactivated vaccines (Tdap, influenza, hepatitis B, COVID) are safe in pregnancy and preconception.
Key distinction: Universal screening (CBC, blood type, rubella, HIV, HepB) is for everyone; targeted screening (TSH, A1c, lead, TB, STIs) is risk-based.
— A1c, fasting glucose, urine albumin/creatinine ratio, creatinine, lipid panel
— Dilated retinal exam preconception (proliferative retinopathy can worsen)
— ECG if long-standing disease or symptoms
— Goal A1c <6.5% before conception; anomaly risk rises sharply with A1c >7%
Step 3 management: Woman with Type 2 DM on metformin + lisinopril + atorvastatin desiring pregnancy → continue metformin (or switch to insulin), stop lisinopril (switch to labetalol/nifedipine), stop statin, optimize A1c <6.5%, start folic acid, retinal exam, baseline UACR and Cr.
— "Do you hope to have (more) children?"
— "How long do you plan to wait?"
— "What will you do to prevent pregnancy until then?"
— "What will you do to stay healthy until then?"
— Low risk: healthy, no chronic disease → folate, vaccines, lifestyle, contraception counseling
— Moderate risk: obesity, mild HTN, controlled asthma, prior GDM → optimize before conception, MFM consult optional
— High risk: poorly controlled DM, advanced CKD, cyanotic CHD, pulmonary HTN, active malignancy on chemo, severe mental illness, recent VTE → MFM consultation pre-pregnancy; some patients counseled to defer or avoid pregnancy
— Prior preterm birth → progesterone candidate, cervical surveillance plan
— Prior preeclampsia → low-dose aspirin 81 mg starting 12–28 weeks (ideally by 16 weeks) in next pregnancy
— Prior GDM → screen with 75g OGTT 4–12 wks postpartum, then q1–3 yrs; weight loss, metformin if prediabetes
— Prior NTD → folic acid 4 mg daily
— Prior stillbirth → workup (autopsy, karyotype, APS, thrombophilia if indicated), close surveillance next pregnancy
Board pearl: Aspirin 81 mg for preeclampsia prevention is indicated for any one high-risk factor (prior preeclampsia, chronic HTN, DM, CKD, SLE/APS, multifetal) or two moderate-risk factors (nulliparity, obesity, age ≥35, family history, Black race, low SES, prior adverse outcome).
— Standard: 400–800 mcg/day, start ≥1 month before conception, continue through 12 weeks (many continue throughout pregnancy via prenatal vitamin)
— High-dose 4 mg/day: prior NTD-affected pregnancy; on antiepileptics (valproate, carbamazepine); folate antagonists (methotrexate, trimethoprim, sulfasalazine); diabetes; obesity (BMI ≥35 often); malabsorption (bariatric, IBD)
— Reduces NTDs by ~70%
— Iron: treat baseline iron deficiency; routine 30 mg in prenatal vitamin
— Iodine: 150 mcg/day (esp. if not using iodized salt)
— Vitamin D: replete deficiency; 600 IU baseline
— Calcium: 1000 mg/day
— Avoid vitamin A >10,000 IU (teratogenic); avoid herbal supplements with unknown safety
— DHA/EPA omega-3: modest benefit; limit high-mercury fish (shark, swordfish, king mackerel, tilefish)
— ACEi/ARB → labetalol, nifedipine, methyldopa
— Warfarin → LMWH (warfarin embryopathy weeks 6–12)
— Statins → discontinue (though recent data more reassuring; stop preconception per current ACOG)
— Isotretinoin → discontinue ≥1 month before; iPLEDGE program mandates 2 forms of contraception and monthly pregnancy tests
— Valproate/topiramate → lamotrigine/levetiracetam
— Methotrexate → discontinue ≥3 months before (men and women)
— Mycophenolate → discontinue ≥6 weeks before; substitute azathioprine
— SSRIs: continue if benefits outweigh risks; sertraline preferred; avoid paroxetine
— Lithium: continue only if essential (Ebstein anomaly risk small but real); fetal echo at 18–22 wks
Step 3 management: Always pair teratogen discontinuation with effective contraception until the switch is complete and stable.
— Use the 5 A's (Ask, Advise, Assess, Assist, Arrange)
— First-line: behavioral counseling + nicotine replacement, bupropion, or varenicline preconception; in pregnancy, behavioral is first-line, NRT if needed
— Smoking → IUGR, preterm birth, placental abruption, stillbirth, SIDS
— No safe amount in pregnancy — fetal alcohol spectrum disorder
— Counsel abstinence once trying to conceive; SBIRT screening
— Balanced diet, Mediterranean pattern; food safety (avoid unpasteurized dairy, deli meats — listeria; raw fish; high-mercury fish)
— Listeriosis ↑20× in pregnancy
— Lead (renovation, pottery, imported cosmetics), mercury (fish), pesticides, organic solvents, ionizing radiation, BPA/phthalates — counsel avoidance
— Cat litter (toxoplasmosis), rodents (LCMV)
CCS pearl: On a preconception CCS case, order folic acid, prenatal vitamin, updated immunizations, screening labs, and counseling (smoking cessation, alcohol, nutrition, IPV) — counseling counts as an order and accrues points.
— Counsel about ↑ infertility, miscarriage, aneuploidy (Down syndrome risk ~1/350 at 35, ~1/100 at 40), preeclampsia, GDM, stillbirth, cesarean
— Offer cell-free DNA screening in pregnancy; preconception, discuss diagnostic options (CVS, amnio)
— Fertility evaluation after 6 months of unsuccessful conception (vs 12 months <35); immediate evaluation ≥40
— Counsel based on stage: Cr >1.4 ↑ risk of progression; Cr >2.5 or eGFR <40 → high risk of accelerated CKD, preeclampsia, preterm birth
— Optimize BP (<130/80), proteinuria, switch ACEi/ARB
— Wait based on tumor type and treatment; fertility preservation counseling before chemo/radiation (Step 3 favorite — must be discussed at diagnosis)
— Anthracycline cardiotoxicity → pre-pregnancy echo
— Tamoxifen: discontinue ≥3 months before conception
Board pearl: A woman newly diagnosed with breast cancer who desires future fertility must be offered referral to reproductive endocrinology for oocyte/embryo cryopreservation before initiating chemotherapy — failure to offer is a board-tested lapse in care.
— Confidentiality is paramount; most states allow minors to consent for contraception, STI care, prenatal care
— Higher rates of unintended pregnancy, STIs, IPV, depression
— Counsel on LARC as first-line contraception (ACOG/AAP); discuss reproductive coercion
— Ask about anatomy, sexual practices, and pregnancy potential rather than assuming
— Transgender men with retained uterus/ovaries can become pregnant; testosterone is teratogenic — must be discontinued before conception, and testosterone is not contraception
— Counsel on options: reciprocal IVF, donor sperm, surrogacy, adoption
— Lesbian couples: donor sperm options, known vs anonymous, legal parentage
— Ashkenazi Jewish: Tay-Sachs, Canavan, familial dysautonomia, Gaucher, Bloom, Fanconi, Niemann-Pick
— French Canadian/Cajun: Tay-Sachs
— African ancestry: sickle cell, β-thalassemia
— Mediterranean, Middle Eastern: β-thalassemia
— Southeast Asian: α-thalassemia (low MCV, normal iron)
— All: CF, SMA, hemoglobinopathies (CBC + hemoglobin electrophoresis)
— Fragile X if family history; consider expanded carrier screening (>100 conditions) — ACOG endorses either approach
Key distinction: Carrier screening identifies asymptomatic carriers of recessive conditions to inform reproductive decisions — it is not the same as prenatal diagnostic testing (CVS/amnio), which detects disease in an existing fetus.
— Uncontrolled DM: spontaneous abortion, congenital anomalies (cardiac, NTD, caudal regression — pathognomonic), DKA, preeclampsia, polyhydramnios, macrosomia, shoulder dystocia, stillbirth
— Uncontrolled HTN: superimposed preeclampsia, IUGR, abruption, preterm delivery
— Uncontrolled thyroid: miscarriage, preterm birth, neurodevelopmental delay (hypo); thyroid storm, low birth weight (hyper)
— Untreated PKU: maternal PKU syndrome — microcephaly, intellectual disability, congenital heart disease in fetus (even unaffected fetus, due to high maternal phenylalanine)
— Untreated epilepsy: convulsions ↑ fetal hypoxia, trauma
— Untreated depression: preterm birth, low birth weight, postpartum depression, impaired bonding
— Folate deficiency → NTDs (spina bifida, anencephaly)
— Rubella → congenital rubella syndrome (cataracts, PDA, deafness)
— Varicella → congenital varicella syndrome
— CMV, toxoplasmosis, Zika → congenital infections
— Alcohol → FAS (smooth philtrum, thin upper lip, small palpebral fissures, growth restriction, ID)
— Tobacco → IUGR, preterm, SIDS
— Teratogenic meds → drug-specific syndromes
Board pearl: Caudal regression syndrome (sacral agenesis) is highly associated with maternal pregestational diabetes — a classic image-stem distractor; transposition of the great arteries and VSD are more common cardiac lesions in diabetic embryopathy.
— Pregestational DM with end-organ disease
— Chronic HTN with target organ damage or on multiple agents
— CKD (especially Cr >1.4 or proteinuria)
— Cardiac disease (CHD, cardiomyopathy, valvular disease, PAH, prior peripartum cardiomyopathy)
— SLE, APS, other connective tissue disease
— Prior severe preeclampsia, HELLP, eclampsia
— Prior preterm birth <34 weeks, recurrent loss, prior stillbirth
— Hemoglobinopathy in both partners
— Maternal PKU, cystic fibrosis, transplant recipients
— BMI ≥40
— Positive carrier screen in both partners
— Prior affected child or known familial mutation (BRCA, Lynch, Huntington, Marfan)
— Consanguinity, recurrent pregnancy loss with abnormal karyotype, advanced age with prior chromosomal abnormality
— Infertility (12 months <35, 6 months ≥35, immediate if ≥40 or known risk)
— Recurrent pregnancy loss (≥2–3)
— Fertility preservation before gonadotoxic therapy
— Same-sex couples and transgender patients planning pregnancy
— Bipolar disorder, severe MDD, psychosis, prior PPD/postpartum psychosis, complex medication regimens
Step 3 management: A woman with a mechanical mitral valve on warfarin desiring pregnancy → coordinate MFM + cardiology + hematology preconception to plan anticoagulation transition (LMWH or dose-adjusted heparin strategies) before she conceives, not after.
— Annual exam emphasizing cancer screening (cervical, breast), contraception, STI screening, immunizations
— Preconception elements should be embedded here as opportunistic counseling, but the well-woman visit's scope is broader and not pregnancy-focused
— Focuses on method selection (LARC tiered first), STI prevention
— Becomes preconception care when patient indicates desire to conceive within 1 year
— Confirms pregnancy, dates, baseline labs
— Many interventions (folate before NTD closure at 28 days, organogenesis-window exposure changes, live vaccines) are already too late — this is the core argument for preconception care
— Care between pregnancies; especially valuable after adverse outcome
— Postpartum visit (now recommended as ongoing 12-week "fourth trimester") is the platform
— Triggered by failure to conceive (12 mo <35, 6 mo ≥35); incorporates preconception elements but adds semen analysis, HSG, ovarian reserve testing
— Risk assessment, pedigree, testing options; complements but does not replace primary care preconception care
Key distinction: Preconception care is anticipatory, delivered when pregnancy is possible but not yet present; prenatal care is reactive, beginning after conception. The teratogenic and metabolic windows that matter most (organogenesis, folate-dependent neural tube closure, A1c-related anomaly risk) close before most women know they are pregnant — hence the preventive-medicine emphasis.
— Workup: pregnancy test first, then TSH, prolactin, FSH/estradiol, consider PCOS labs; don't skip the basics
— Must stop isotretinoin and complete iPLEDGE requirements; pregnancy test before and after; counsel 1-month washout
— Do not abruptly taper; buprenorphine or methadone MAT during pregnancy improves outcomes vs withdrawal; coordinate with addiction medicine and MFM
— ≥2–3 losses → APS antibodies, TSH, prolactin, karyotype of products and both parents, uterine cavity evaluation (saline sonohysterogram/HSG)
— Always ask about pregnancy plans before refilling methotrexate, isotretinoin, warfarin, mycophenolate, valproate
— Becomes interconception care opportunity — contraception, birth spacing, screening for next pregnancy risks
— Counsel wait 12–24 months post-op; effective contraception (non-oral preferred after malabsorptive procedures); micronutrient surveillance
— Time-sensitive; refer to REI before treatment starts
Board pearl: When a Step 3 stem mentions a reproductive-age woman on any of these meds — methotrexate, warfarin, ACEi/ARB, valproate, isotretinoin, mycophenolate, lithium, statins — assume the next best step is to confirm contraception and/or counsel preconception change, even if pregnancy isn't the chief complaint.
— Folic acid is established (continue throughout pregnancy)
— Teratogenic medications already switched
— Chronic disease optimized (A1c, BP, TSH, mood)
— Immunizations updated
— Genetic carrier results in hand
— Reproductive plan documented
— First prenatal visit ideally by 10 weeks
— Confirm dating, prenatal labs, anatomy ultrasound at 18–22 wks
— Aspirin 81 mg by 12–16 wks if preeclampsia risk factors
— Tdap 27–36 wks, influenza any time, COVID-19 per current guidance, RSV maternal vaccine 32–36 wks (seasonal)
— GDM screening 24–28 wks (or first trimester if risk factors)
— Visit within 3 weeks, comprehensive by 12 weeks
— Screen for postpartum depression (EPDS or PHQ-9) — repeatedly
— Resume or initiate contraception (LARC immediately postpartum is safe; avoid combined estrogen contraceptives in first 3 weeks due to VTE risk; longer if breastfeeding or other risks)
— Re-screen for diabetes if GDM (75g OGTT 4–12 wks postpartum, then q1–3 yrs)
— Cardiovascular risk counseling if preeclampsia/GDM (lifetime ↑CV risk)
— Bone health if prolonged lactation + amenorrhea
— Plan birth spacing ≥18 months
Step 3 management: A woman with prior GDM presents 9 months postpartum for "well visit." Order 75g 2-hour OGTT (if not done), counsel 5–7% weight loss, 150 min/week exercise, consider metformin if prediabetes, and start folic acid + interconception planning for next pregnancy — her lifetime DM risk is ~50%.
— Healthy patient actively trying: counsel at well-woman visit, follow up if not pregnant in 6–12 months
— Chronic disease optimization phase: every 1–3 months until targets met (e.g., A1c <6.5%, BP <130/80, TSH <2.5, stable mood)
— High-risk MFM co-management: per specialist
— Diabetes: A1c q3 months, fasting/postprandial glucoses, retinal exam yearly, UACR yearly
— HTN: home BP log, q1–3 month visits during med adjustment
— Thyroid: TSH q6–8 weeks during dose titration; then q3 months until stable
— Epilepsy: seizure diary, drug levels, switch monitoring by neurology
— Depression: PHQ-9 q month during med change; ensure stable ≥3–6 months before conception
— Weight: monthly during active loss; aim 5–10% pre-conception in obese patients
— Folic acid adherence
— Contraception adherence (until ready)
— Lifestyle (tobacco, alcohol, exercise, diet)
— IPV screening (each visit if risk)
— Immunization gaps
— Medication reconciliation
— Ovulation prediction (LH kits, cycle day 14 in 28-day cycle, cervical mucus)
— Intercourse every 1–2 days around ovulation window
— Pregnancy test if menses delayed
— <35: after 12 months of unprotected intercourse
— ≥35: after 6 months
— ≥40 or known risk (oligomenorrhea, prior pelvic surgery, chemo, endometriosis, known male factor): immediate evaluation
CCS pearl: In a CCS preconception case, advance the clock in 1–3 month intervals while titrating chronic disease meds, repeating labs at each visit until targets are met — then green-light conception.
— Counseling must be non-directive — present risks/benefits, respect patient choice even if she opts to proceed with high-risk pregnancy
— Document counseling about teratogen risk, recommended alternatives, and patient decision (medicolegally critical for isotretinoin, warfarin, methotrexate, valproate)
— Avoid coercion or paternalism, especially with patients of marginalized identity, disability, or substance use history
— Most US states permit minors to consent for contraception, STI testing/treatment, and prenatal care without parental notification — know your state
— Balance confidentiality with mandatory reporting of statutory rape based on age differential and state law
— Suspected child abuse, statutory rape, IPV in some states (laws vary; IPV reporting generally not mandatory in most states for competent adults — respect autonomy and safety planning)
— Federally mandated REMS: 2 forms of contraception, monthly negative pregnancy tests, prescriber/pharmacy/patient registration — a Step 3 patient-safety favorite
— Substance use disorder: do not withhold MAT due to pregnancy desire; counsel about NAS but emphasize MAT > untreated OUD
— Disability: presumption of decisional capacity; provide accessible counseling; involve guardian only when legally appropriate
— Pre- and post-test counseling required; results have implications for partner, future children, insurance (GINA protects health insurance/employment but not life, disability, or long-term care insurance)
— When switching teratogens, explicit handoff between specialists and clear patient instructions; bridge contraception until therapeutic substitute is stable
— Medication reconciliation at every visit to avoid teratogen reintroduction
Board pearl: A 16-year-old presents for contraception and asks that her parents not be told. In nearly all US jurisdictions, provide confidential contraceptive services; breaching confidentiality without cause is both unethical and legally problematic.
Key distinction: Folate prevents NTDs (closure by day 28); iodine prevents cretinism; A1c control prevents diabetic embryopathy — different nutrients/parameters, different windows.
— 28-year-old at well-visit hopes to conceive in 6 months. Best next step? → Folic acid 400 mcg daily, update vaccines, screen labs, counsel lifestyle.
— Woman with T2DM A1c 8.5% on metformin + lisinopril + atorvastatin wants pregnancy. Best next step? → Switch lisinopril to labetalol/nifedipine, stop statin, intensify glycemic control (target A1c <6.5%), folic acid (often 4 mg), retinal exam, contraception until optimized.
— Woman on isotretinoin with positive pregnancy test. → Counsel risks, options including termination; if continuing, MFM and detailed anatomy ultrasound. Stop isotretinoin immediately.
— Prior spina bifida infant. Next pregnancy preparation? → Folic acid 4 mg/day ≥1 month before conception.
— Prior severe preeclampsia. → Aspirin 81 mg 12–16 wks in next pregnancy.
— Non-immune to rubella, wants to conceive. → MMR now, avoid pregnancy 4 weeks.
— Both partners Ashkenazi Jewish. → Offer Ashkenazi panel (Tay-Sachs etc.) + CF, SMA, hemoglobinopathies.
— Both partners African ancestry with microcytic anemia. → Hemoglobin electrophoresis both partners; if both sickle trait, genetic counseling.
— 38-year-old trying 6 months unsuccessfully. → Refer to REI now (not after 12 months).
— Recent gastric bypass wants pregnancy. → Wait 12–24 months, effective contraception, micronutrient screen.
— → MFM + cardiology preconception to plan LMWH/heparin transition.
— → 75g OGTT 4–12 weeks postpartum, lifestyle, interconception plan.
Step 3 management trap: When the stem says "she is not currently planning pregnancy" but is reproductive-age and on a teratogen — the answer is still preconception counseling + reliable contraception, not "no action needed."
Preconception care is the systematic optimization of biomedical, behavioral, and social health before pregnancy — delivered opportunistically at every reproductive-age primary care visit — because the windows that matter most (organogenesis, neural tube closure, glycemic and teratogen exposures) close before most women know they are pregnant.
Board pearl: If a Step 3 stem features a reproductive-age woman and any teratogen, any uncontrolled chronic disease, or any non-immune vaccine status — the single best next step is preconception counseling and intervention now, before pregnancy occurs.